DavidKavanagh National Renal Complement Therapeutics Centre United Kingdom

DavidKavanagh
David Kavanagh is the Professor of Complement Therapeutics at the National Renal Complement Therapeutics Centre (NRCTC). He graduated in Medicine and Immunology from the University of Glasgow in 1998 and obtained his PhD from Newcastle University in 2006. He subsequently undertook a Postdoctoral Fellowship at Washington University School of Medicine, St. Louis and a Kidney Research UK Fellowship at the University of Edinburgh. For his work defining the role of complement in aHUS, he was awarded the Renal Association’s Young Investigator award. David moved to Newcastle to start his own lab in 2008 with a Wellcome Trust Fellowship to continue his work on complement mediated renal diseases. In addition, David is chief investigator on several clinical trials of novel complement therapeutics in C3G and aHUS. More recently David has also focused on the genetics of the complement system in the eye. David was academic founder of Gyroscope Therapeutics which is using gene therapy to treat Age Related Macular Degeneration, the commonest cause of blindness in the developed world. This therapy is based on his finding of the causative role of complement factor I haploinsufficiency in disease pathogenesis. Gyroscope therapeutics was recently acquired by Novartis following initial clinical trials.
Upload Picture
https://storage.unitedwebnetwork.com/files/1099/970081dbcef137b22c9f52ecf5c8098b.jpg
First Name
David
Last Name
Kavanagh
Institution
Country.
United Kingdom

Friday, February 7, 2025

Time Session
9:45 a.m.
11:15 a.m.
ArvindBagga Chair arvindbagga@hotmail.comIndia
VinayRathore Chair vinayrathoredm@aiimsraipur.edu.inIndia
  • Outcomes From the ISN Haemolytic Uraemic Syndromes Forum: A Comprehensive Review
    DavidKavanagh Speaker National Renal Complement Therapeutics Centre United Kingdom
  • Differential Diagnosis and Treatment of TMAs in Pregnancy
    ShilpanjaliJesudason Speaker Royal Adelaide Hospital and University of Adelaide, AustraliaAustralia
  • Antiphospholipid Syndrome in Pregnancy
  • aHUS in Paediatric Populations
    Lap Tak Alison MA Speaker Hong Kong, China
  • Q&A
Parijat Hall 201
4:15 p.m.
5:15 p.m.
AmitGovil Chair amit.govil@uc.eduUnited States
S AnanthKarumanchi Chair SAnanth.Karumanchi@csmc.eduUnited States
  • The Complement System in C3G and IgAN: A Pathophysiologic Perspective
    HernánTrimarchi Speaker HOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
  • The Complement System in C3G: Updated Therapeutic Approaches
    DavidKavanagh Speaker National Renal Complement Therapeutics Centre United Kingdom
  • The Complement System in IgAN: An Updated Therapeutic Approach
    HeatherReich Speaker University of Toronto, University Health NetworkCanada
  • Q&A
Kumudini Hall 301